Abstract
Outcomes in patients with EBV+ PTLD treated with allogeneic EBV‐specific T‐cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have